Leukadherin-1 (LA1), a novel small molecule agonist of integrin CD11b/CD18, can increase the extent of CD11b/CD18-dependent cell adhesion of transfected cells and of primary human and mouse neutrophils (EC50 =4µM in vitro), which resulted in decreased chemotaxis and transendothelial migration. LA1 can also decrease leukocyte recruitment and reduced arterial narrowing after injury in rats. Moreover, compared to a known integrin antagonist, LA1 preserved kidney function better in a mouse model of experimental nephritis. It inhibited leukocyte recruitment by increasing leukocyte adhesion to the inflamed endothelium, which was reversed with a blocking antibody.